loading
Plus Therapeutics Inc stock is traded at $1.185, with a volume of 20,600. It is up +1.28% in the last 24 hours and down -17.71% over the past month. Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$1.17
Open:
$1.21
24h Volume:
20,600
Relative Volume:
0.27
Market Cap:
$6.90M
Revenue:
-
Net Income/Loss:
$-13.32M
P/E Ratio:
-0.1968
EPS:
-6.02
Net Cash Flow:
$-13.01M
1W Performance:
-0.42%
1M Performance:
-17.71%
6M Performance:
-47.10%
1Y Performance:
-54.94%
1-Day Range:
Value
$1.17
$1.21
1-Week Range:
Value
$1.16
$1.42
52-Week Range:
Value
$1.145
$2.6702

Plus Therapeutics Inc Stock (PSTV) Company Profile

Name
Name
Plus Therapeutics Inc
Name
Phone
737.255.7194
Name
Address
4200 MARATHON BLVD., AUSTIN, TX
Name
Employee
20
Name
Twitter
@plustxinc
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
PSTV's Discussions on Twitter

Compare PSTV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
PSTV 1.18 6.90M 0 -13.32M -13.01M -6.02
VRTX 467.37 119.83B 10.63B -479.80M -1.35B 13.33
REGN 760.78 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 564.61 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.58 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.54 24.08B 3.30B -501.07M 1.03B 11.54

Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-25-21 Initiated Ladenburg Thalmann Buy
Oct-16-20 Initiated Maxim Group Buy

Plus Therapeutics Inc Stock (PSTV) Latest News

pulisher
05:00 AM

Earnings call: Plus Therapeutics reports progress and financials for Q3 2024 - Investing.com

05:00 AM
pulisher
Nov 17, 2024

Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 17, 2024
pulisher
Nov 15, 2024

Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance

Nov 15, 2024
pulisher
Nov 15, 2024

Plus: Q3 Earnings Snapshot - Houston Chronicle

Nov 15, 2024
pulisher
Nov 14, 2024

Plus Therapeutics Advances Radiotherapeutics in Q3 2024 - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

PLUS THERAPEUTICS Inc (PSTV) Quarterly 10-Q Report - Quartzy

Nov 14, 2024
pulisher
Nov 11, 2024

Leptomeningeal Metastases Clinical Trials 2024: FDA - openPR

Nov 11, 2024
pulisher
Nov 09, 2024

Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics - Seeking Alpha

Nov 09, 2024
pulisher
Nov 08, 2024

Sitravatinib Plus Nivo-Ipi Appears Safe, Active in ccRCC - Cancer Therapy Advisor

Nov 08, 2024
pulisher
Nov 07, 2024

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Nov 07, 2024
pulisher
Nov 06, 2024

Plus Therapeutics partners with SpectronRx for cancer therapy - Investing.com India

Nov 06, 2024
pulisher
Nov 06, 2024

Plus Therapeutics partners with SpectronRx for cancer therapy By Investing.com - Investing.com UK

Nov 06, 2024
pulisher
Nov 06, 2024

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership - GlobeNewswire

Nov 06, 2024
pulisher
Nov 06, 2024

Plus Thera teams up with SpectronRx for radiotherapy production - The Pharma Letter

Nov 06, 2024
pulisher
Nov 05, 2024

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024 - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Plus Therapeutics (PSTV) Sets Q3 2024 Earnings Call for November 14 | PSTV Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 01, 2024

Plus Therapeutics granted extension by Nasdaq - Investing.com

Nov 01, 2024
pulisher
Oct 29, 2024

Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail

Oct 29, 2024
pulisher
Oct 29, 2024

Plus Therapeutics Showcases Leptomeningeal Metastases - GlobeNewswire

Oct 29, 2024
pulisher
Oct 27, 2024

Simulations Plus, Inc. (NASDAQ:SLP) Receives $56.00 Consensus Price Target from Analysts - Defense World

Oct 27, 2024
pulisher
Oct 24, 2024

Metastatic Colorectal Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Daiichi Sankyo Company, Mirati Therapeutics, Apollomics - Barchart

Oct 24, 2024
pulisher
Oct 21, 2024

Evaluating Immunotherapy as Systemic Therapy Plus RT in Early-Stage NSCLC - Cancer Network

Oct 21, 2024
pulisher
Oct 21, 2024

Colorectal Cancer Pipeline Overview 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa Pharma - The Globe and Mail

Oct 21, 2024
pulisher
Oct 19, 2024

Curio Digital Therapeutics Applauded by Frost & Sullivan for Enhancing Women's Maternal Mental Healthcare with its MamaLift and MamaLift Plus Solutions - The Malaysian Reserve

Oct 19, 2024
pulisher
Oct 15, 2024

Prescription Digital Therapeutics for Mental Health: A New Era in Psychiatry - Psychiatry Advisor

Oct 15, 2024
pulisher
Oct 13, 2024

SalioGen Therapeutics hit by layoffs, as gene-editing biotechs continue to struggle - STAT

Oct 13, 2024
pulisher
Oct 06, 2024

Ultra-Hypofractionated Radiation May Mitigate Breast Cancer Recurrence - Cancer Network

Oct 06, 2024
pulisher
Oct 01, 2024

Plus Therapeutics reports progress in brain cancer trial - Investing.com

Oct 01, 2024
pulisher
Oct 01, 2024

Plus Therapeutics reports progress in brain cancer trial By Investing.com - Investing.com Canada

Oct 01, 2024
pulisher
Oct 01, 2024

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 01, 2024
pulisher
Oct 01, 2024

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting - ForexTV.com

Oct 01, 2024
pulisher
Oct 01, 2024

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update - GlobeNewswire

Oct 01, 2024
pulisher
Oct 01, 2024

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of ... - The Bakersfield Californian

Oct 01, 2024
pulisher
Sep 30, 2024

Dow Tumbles Over 200 Points; Carnival Posts Upbeat Earnings - Benzinga

Sep 30, 2024
pulisher
Sep 30, 2024

The 3 Best Light Therapy Lamps of 2024 | Reviews by Wirecutter - Wirecutter, A New York Times Company

Sep 30, 2024
pulisher
Sep 25, 2024

Celldex drug reduces chronic hive activity, but patient discontinuations raise questions - STAT

Sep 25, 2024
pulisher
Sep 24, 2024

Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease - Frontiers

Sep 24, 2024
pulisher
Sep 23, 2024

Elevar Therapeutics Resubmits New Drug Application to FDA - GlobeNewswire

Sep 23, 2024
pulisher
Sep 23, 2024

Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Boosted by CARES-310 Leading Overall Survival Analysis - Yahoo Finance

Sep 23, 2024
pulisher
Sep 22, 2024

Bluejay Diagnostics (NASDAQ:BJDX) versus Plus Therapeutics (NASDAQ:PSTV) Head-To-Head Review - Defense World

Sep 22, 2024
pulisher
Sep 19, 2024

Plus Therapeutics to present at CNS Annual Meeting By Investing.com - Investing.com Canada

Sep 19, 2024
pulisher
Sep 19, 2024

From 'science fiction to reality': New George Church-founded biotech raises $75M for cell therapy platform - Fierce Biotech

Sep 19, 2024
pulisher
Sep 18, 2024

Plus Therapeutics to present at CNS Annual Meeting - Investing.com

Sep 18, 2024
pulisher
Sep 18, 2024

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 - GlobeNewswire

Sep 18, 2024
pulisher
Sep 18, 2024

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting - StockTitan

Sep 18, 2024
pulisher
Sep 18, 2024

Gilead Sciences Therapeutic Areas: Virology, Oncology & Inflammation - Gilead Sciences

Sep 18, 2024
pulisher
Sep 17, 2024

Plus Therapeutics director buys $6k worth of shares By Investing.com - Investing.com Canada

Sep 17, 2024
pulisher
Sep 17, 2024

Plus Therapeutics director buys $6k worth of shares - Investing.com

Sep 17, 2024
pulisher
Sep 17, 2024

Plus Therapeutics director acquires $8.5k in stock - Investing.com

Sep 17, 2024

Plus Therapeutics Inc Stock (PSTV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Plus Therapeutics Inc Stock (PSTV) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Hawkins Richard J
Director
Sep 12 '24
Buy
1.35
6,285
8,512
11,188
Petersen Greg
Director
Sep 11 '24
Buy
1.35
12,500
16,875
48,921
Clowes Howard
Director
Sep 11 '24
Buy
1.34
5,000
6,681
26,497
HEDRICK MARC H
Chief Executive Officer
Sep 10 '24
Buy
1.23
8,000
9,839
20,425
Sims Andrew John Hugh MacIntyr
Chief Financial Officer
Sep 10 '24
Buy
1.27
4,098
5,204
9,815
Sims Andrew John Hugh MacIntyr
Chief Financial Officer
May 08 '24
Buy
2.04
4,902
10,000
5,717
HEDRICK MARC H
Chief Executive Officer
May 08 '24
Buy
2.04
12,255
25,000
12,425
Petersen Greg
Director
May 08 '24
Buy
2.04
12,255
25,000
36,421
Clowes Howard
Director
May 08 '24
Buy
2.04
9,804
20,000
21,497
Hawkins Richard J
Director
May 08 '24
Buy
2.04
4,902
10,000
4,903
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.25
price down icon 0.96%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):